Health Management Associates, Inc.
Health Management Associates — Proxy Contest (July 2013)
52 slides from Health Management Associates's proxy contest presentation, Jul 19, 2013
Slide 1: Revitalize HMA - The Case for Change
Revitalize HMA - The Case for Change Presentation to HMA Shareholders July 2013
Slide 2: Executive Summary - The Case for Change at HMA
PAGE 2 Executive Summary - The Case for Change at HMA 1 Consistent track record of underperformance 2 Substandard financial management and focus 3 Elevated number of compliance related issues and concerns 4 Misalignment between Board direction and shareholder priorities 5 Sitting Board is insular an
Slide 3: Executive Summary - The Case for Change at HMA
PAGE 3 Executive Summary - The Case for Change at HMA The Lost Decade In the decade ending 2012, HMA, under the direction and guidance of substantially all of the sitting Board, delivered <1% total shareholder value while investors in the Hospital Group and the S&P garnered an 39% and 99% total shar
Slide 4: Executive Summary - Capital allocation, CEO turnover, incentive plans
PAGE 4 Myopic focus on M&A, no balanced capital allocation strategy During the Lost Decade management and the Board followed a myopic strategy of unfocused M&A growth HMA demonstrated 86% EBITDA growth in the 10 years ending 2012, but <1% total shareholder return HMA is the only company in the Hospi
Slide 5: Executive Summary - Shareholder-unfriendly defensive tactics
PAGE 5 Executive Summary - The Case for Change at HMA Shareholder-unfriendly defensive tactics Rather than constructively engaging shareholders in dialogue, Board put in place a Poison Pill Board stated that it hired bankers and legal advisors "in connection with accumulation of shares by Glenview"
Slide 6: The Lost Decade - Consistent Underperformance
(CHART) PAGE 6 The Lost Decade - Consistent Underperformance Source: Bloomberg total shareholder return analysis assuming dividends reinvested in security. 1. "Hospital Group" includes HCA, THC, CYH, LPNT, and UHS except where indicated. 2. HCA reflects total compounded shareholder return from 1/1/0
Slide 7: Total Shareholder Return - Consistent Underperformance
PAGE 7 Total Shareholder Return - Consistent Underperformance HMA's total shareholder return has sharply and consistently lagged other publicly traded hospital companies Total Shareholder Return 3-year period ending 5/6/13 Total Shareholder Return 5-year period ending 5/6/13 Total Shareholder Return
Slide 8: The Board is Now Searching for Their 5th CEO in 13 Years
PAGE 8 The Board is Now Searching for Their 5th CEO in 13 Years CEO Gary Newsome's departure announced May 28 New CEO expected by Newsome's departure July 31 Board Committee leading the search for a new CEO is comprised of: William Schoen Kent Dauten Robert Knox Donald Kiernan Dauten & Knox also ser
Slide 9: Substandard Financial Management and Focus
PAGE 9 Substandard Financial Management and Focus Source: Company filings, press releases, earnings calls and Morgan Stanley equity research. Guidance based on HMA investor communications/documents: 1) 10/22/02 Q4 earnings call transcript, 2) 10/21/03 Q4 earnings call transcript, 3) 10/26/04 Q4 earn
Slide 10: Substandard Financial Management and Focus - Admissions Growth
PAGE 10 Substandard Financial Management and Focus Note: "Hospital Group" includes HCA, THC, CYH, LPNT, and UHS (acute only). Source: Company filings, press releases, earnings calls and Morgan Stanley equity research. Same-store Admissions Growth Relative to its hospital peers, HMA has demonstrated
Slide 11: HMA Guidance vs Performance
PAGE 11 Metric HMA Guidance Consensus Estimates HMA Performance Result (Relative to Guidance) Admissions (2010)1 1% to 2% -1.8% MISSED (2.8-3.8%) Admissions (2011)2 0% to 2% -4.0% MISSED (4.0-6.0%) Earnings per Share (2011)2 72-76c 71c MISSED (1.4-6.6%) Admissions (2012)2 -2% to 0% -4.8% MISSED (2.8
Slide 12: CFO Credibility on Provider Fees and Exchange Contracts
PAGE 12 AL, OK, NC, PA, and MS all paid industry provider fees in 3Q12, but the CFO claimed HMA received none Analyst on earnings call: "Did you see any provider fees from any of your states in that 6.9% number?"1 HMA CFO: "No." Financial leadership failed to establish credibility with the investor
Slide 13: CFO Shows Lack of Seriousness in Meetings
PAGE 13 The CFO consistently shows a lack of seriousness in meetings and responds to questions with laughter and non-responsive answers - even after major earnings misses and significant declines in the stock On April 10, HMA pre-announced poor 1Q13 results: HMA missed consensus EBITDA by 21%, conse
Slide 14: Suboptimal Capital Allocation Policy - Interest Rate Risk
Suboptimal Capital Allocation Policy 1. "Long-Term Interest Rates", Ben S. Bernanke, p. 9-10. 2. HMA 1Q13 earnings call transcript. 3/1/13: Remarks by Ben Bernanke at the Annual Monetary/Macroeconomics Conference "The basic message is clear--long-term interest rates are expected to rise gradually ov
Slide 15: Suboptimal Capital Allocation Policy - Variable Rate Debt
Suboptimal Capital Allocation Policy Fixed Rate Debt (% of total) Variable Rate Debt (% of total) Hospital Competitors1 83% 17% HMA2 41% 59% 1. Weighted average fixed/variable debt percentages of CYH, HCA, LPNT, THC, UHS and VHS net of interest rate swaps. Sourced from most recent 10-Q filings. 2. P
Slide 16: Compliance Concerns Have Led to Multiple Investigations
PAGE 16 Compliance Concerns Have Led to Multiple Investigations Former CEO of Physicians Regional Medical Center Michael Mastej filed a lawsuit against HMA in 2010 Mastej's case claimed that HMA used incentives to increase physician Medicare patient referrals to HMA hospitals Similar allegations of
Slide 17: Weak Corporate Governance - Compliance / Quality
Weak Corporate Governance - Compliance / Quality Notes: While compliance issues are presently handled through HMA's Audit Committee, the one Board member with prior Chief Legal and Chief Compliance Officer experience does not sit on the Audit Committee. HCA established Audit and Compliance Committee
Slide 18: Weak Corporate Governance - Compensation
PAGE 18 Weak Corporate Governance - Compensation Source: Company proxy statements. 1. HCA added quality as a metric in 2010 (previously tied compensation to quality as far back as 1997). LPNT added quality as a metric in 2007. THC added quality as a metric in 1993 or earlier. Unlike its peers, execu
Slide 19: Misaligned Incentive Compensation Tied to EBITDA
PAGE 19 The Board's misaligned executive incentive compensation structure has been tied exclusively to aggregate EBITDA growth - as opposed to any per share metrics Board has misguided view that aggregate measures like EBITDA growth drive share price performance, whereas they place no emphasis on pe
Slide 20: HMA 2012 Performance and Management Incentives
PAGE 20 HMA 2012 Performance HMA Guidance Actual Result Adjusted EBITDA1 $875-925M $871M MISSED (0.4-6%) Earnings per Share1 80-90c 75c MISSED (6-17%) Admissions -2% to 0% -4.8% MISSED (2.8-4.8%) HMA 2012 Management Incentives Result Performance Target set by Board: Adjusted EBITDA Target: $924M Act
Slide 21: HMA Misapplied Management Incentive Compensation
PAGE 21 HMA Misapplied Management Incentive Compensation Paid to Hospitals that show "meaningful use" of electronic records Paid by the federal government Established in 2009 by the "stimulus package" Available 2011-2016 HMA's 2012 guidance cited an estimated $90- 120M in HITECH meaningful use reimb
Slide 22: HMA Misapplied Management Incentive Compensation
PAGE 22 HMA Misapplied Management Incentive Compensation Date Reference HMA Management Announcement HITECH Incentive Payments in Adj. Adjusted EBITDA January 9, 2012 HMA Press Release Issued 2012 guidance: Adjusted EBITDA of $875-925M Excluded March 26, 2012 Barclays High-Yield Bond Conference Reite
Slide 23: HMA Misapplied Management Incentive Compensation
PAGE 23 HMA Misapplied Management Incentive Compensation On a May 3rd call with Glenview, HMA's CFO insisted that the $924M Performance Target included HITECH incentive payments On a subsequent call on May 15th with Glenview, Chairman Schoen & Lead Director Knox confirmed the $924M Performance Targe
Slide 24: Ineffective Incentives & Strategy Led to Near Zero Growth
PAGE 24 Ineffective Incentives & Strategy Have Led to Near Zero Shareholder Growth in 10 Years According to a recent HMA proxy, the Board "believes that Adjusted EBITDA provides a simple and understandable measure of our recurring profitability and it is highly correlated to our stock price performa
Slide 25: The Board Has Weak Strategic Vision
PAGE 25 The Board Has Weak Strategic Vision HMA claims to have targeted EBITDA growth through M&A... ...but their poor track record is reflected in HMA's stock price The Board recently hired outside advisors to help focus its M&A strategy, citing the discontinuity of prior acquisitions and their pri
Slide 26: Suboptimal Capital Allocation Policy
PAGE 26 Suboptimal Capital Allocation Policy (CHART) Share repurchase ($M) Share repurchase 0% 11% 10% 46% 70%1 23% M&A 100% 78% 87% 54% 26% 29% Dividend 0% 11% 3% 0% 3% 48% Total ($M) $656 $715 $846 $591 $1,125 $6,622 Average price of repurchase N/A $39.12 $24.72 $36.69 $23.652 $18.61 Stock price o
Slide 27: Suboptimal Capital Allocation Policy - Share Repurchases
1. EBITDA estimates reflect the mid-point of HMA's guidance respectively. 2. Balance sheet stats as of 1Q12 actual. 3. Balance sheet stats as of 3Q12 actual. Historical intransigence about considering stock repurchases demonstrates a deep seated bias by HMA's Board to even consider share repurchases
Slide 28: Capital Allocation to Share Repurchase Consistently Outperforms
PAGE 28 Capital Allocation to Share Repurchase Consistently Outperforms Companies that consistently invested their cash flow and resources in a share repurchase program have generated material outperformance over the past 5, 10 and 15 year periods, leading to an average of more than 4% greater annua
Slide 29: Excessive Tenure: The Board is Insular & Stale
PAGE 29 Excessive Tenure: The Board is Insular & Stale HMA's peers have not made the same mistake Average tenure for the HMA Board: ~17 years HMA Director Year Appointed Tenure (Years) Dauten 1981 32 Schoen 1983 30 Knox 1985 28 Westerfield 2000 13 Kiernan 2001 12 Steere 2003 10 O'Meara 2005 8 Goldsc
Slide 30: Poison Pill Rights Plan
PAGE 30 "The Rights will cause substantial dilution to any person or group that attempts to acquire the Corporation without the approval of the Board of Directors" "The determination of the Board of Directors to redeem the Rights may be made on such basis and be subject to such conditions as the Boa
Slide 31: Board Failure to Consider Alternatives - May 2013 Timeline
PAGE 31 Our View: Board Failure to Consider Alternatives to Create Shareholder Value May 2013 Timeline Hostile actions indicative of an insular board No calls after the Annual Meeting, despite two offers for a Board-level meeting HMA cancelled its management meeting with Glenview, telling investors
Slide 32: Defensive Insular Tactics Are Not New - 2007 Case Study
PAGE 32 Defensive Insular Tactics Are Not a New Phenomenon - 2007 Case Study 1. Per Bloomberg assuming divided reinvestment. 2. Note that the total shareholder return assuming dividends reinvested in security from 1/17/2007 through 5/6/2013 has been 0.2% . Given the LBO of HCA earlier in 2006, there
Slide 33: Fiduciary Duties and Change of Control
PAGE 33 Fiduciary Duties and Change of Control HMA's Board of Directors included a "poison proxy put" provision in its 2011 Credit Agreement ($2.2 billion outstanding) that results in an event of default if a majority of the Board is replaced by Glenview's nominees The Credit Agreement has a "dead h
Slide 34: Shareholders' Value-Enhancing Solution: Revitalize HMA
PAGE 34 Shareholders' Value-Enhancing Solution: Revitalize HMA
Slide 35: Executive Summary - Revitalize HMA
PAGE 35 Executive Summary - Revitalize HMA "And in the specific case of HMA, we think that this is precisely the sort of action that could fix long-standing problems. In short, we think that Glenview is pursuing precisely the correct course and believe that it can be successful in building a consens
Slide 36: Elect a Blue-Chip Board
PAGE 36 Executive Summary - Revitalize HMA Elect a blue-chip Board - to serve for the benefit of ALL shareholders, not for ONE shareholder The nominees put forth represent leaders in their fields with expertise in areas critical to success and prosperity at HMA - including facilities and payer manag
Slide 37: Maintain Continuity
PAGE 37 Executive Summary - Revitalize HMA Glenview Capital has identified a team from Alvarez & Marsal (A&M) to help transition as potential management during the initial transition and stabilization period at HMA, as necessary Guy Sansone, Head of the Healthcare Group, has over 17 years of experie
Slide 38: A Holistic Approach to Addressing the Current Challenges at HMA
PAGE 38 A Holistic Approach to Addressing the Current Challenges at HMA The Fresh Alternative for HMA Proven managers, leaders and professionals capable of tackling the myriad of operating, cultural, financial and regulatory issues at HMA Mary Taylor Behrens Experience in executive compensation, hum
Slide 39: The Right Nominees for Shareholder Value at HMA
PAGE 39 The Right Nominees for Shareholder Value at HMA Characteristics of Proposed Nominees Our View: Experience of Proposed Nominees vs. Current Board Leaders in their respective fields Broad executive level leadership Successful track-record in hospital operations Turn-around experience Legal and
Slide 40: New Proposed HMA Board Structure and Committee Composition
PAGE 40 New Proposed HMA Board Structure and Committee Composition Audit Committee John McCarty (Chair) Kirk Gorman Stephen Guillard Compensation Committee Compensation Committee Governance Committee Steven Epstein (Chair) Stephen Guillard John McCarty Peter Urbanowicz Mary Taylor Behrens (Chair) St
Slide 41: A Constructive Path Forward
PAGE 41 A Constructive Path Forward Should long-term independence be the value maximizing strategy, then embark on a long-term HR program to build management talent depth and culture Evaluate with an open mind all avenues for shareholder value creation Establish an interim management team with exper
Slide 42: Maintain Continuity - Proven Transitional Management
PAGE 42 Maintain Continuity - Proven Transitional Management Glenview Capital has identified a team from Alvarez & Marsal (A&M) to help transition as potential management during the initial transition and stabilization period at HMA, as necessary Guy Sansone, Head of the Healthcare Group, has over 1
Slide 43: Mary Taylor Behrens
PAGE 43 Mary Taylor Behrens Current President of Newfane Advisors, Inc. Former Head of Merrill Lynch Investment Managers, Americas Region Board member of Sagent Pharmaceuticals, Inc. Career Highlights and Experience Board of Directors Experience Founded Newfane Advisors, a private consulting firm, i
Slide 44: Steven Epstein
PAGE 44 Steven Epstein Founder and Senior Health Partner of Epstein Becker & Green, P.C. Current board member of multiple companies in the healthcare sector Career Highlights and Experience Board of Directors Experience Senior Partner of Epstein Becker & Green, a leading law firm in health care law
Slide 45: Kirk Gorman
PAGE 45 Kirk Gorman Current Executive Vice President and CFO of Jefferson Health System Former Senior Vice President and CFO of Universal Health Services Chairman of the board of CardioNet, Inc. Career Highlights and Experience Board of Directors Experience Currently the Executive Vice President and
Slide 46: Stephen Guillard
PAGE 46 Stephen Guillard Former COO and Executive Vice President of HCR ManorCare, Inc. Former Chairman, President and CEO of Harborside Healthcare Corp. Former Co-Founder, President and CEO of Diversified Health Services Career Highlights and Experience Board of Directors Experience Was responsible
Slide 47: John McCarty
PAGE 47 John McCarty Former Executive Vice President and Chief Financial Officer of SHPS, Inc. Former Chief Financial Officer of LabOne Inc. Former Senior Vice President and CFO of eai Healthcare Staffing Solutions Career Highlights and Experience Additional Relevant Experience Served as a consultan
Slide 48: JoAnn Reed
PAGE 48 JoAnn Reed Current Healthcare Services Consultant Director and Audit Committee member of American Tower, Inc. Career Highlights and Experience Board of Directors Experience Served as Chief Financial Officer of Medco Health Solutions from 1996 to March 2008 and as an advisor to the Company's
Slide 49: Steven Shulman
PAGE 49 Steven Shulman Senior Advisor of Water Street Healthcare Partners Former Chairman, Chief Executive Officer of Magellan Health Services Former Chairman, President and CEO of Prudential Healthcare Inc. Career Highlights and Experience Board of Directors Experience Current Managing Partner at S
Slide 50: Peter Urbanowicz
PAGE 50 Peter Urbanowicz Managing Director at Alvarez & Marsal's Healthcare Group Former Executive VP, General Counsel and Secretary of Tenet Healthcare Former Deputy General Counsel of Dept. of Health and Human Services Career Highlights and Experience Board of Directors Experience Has led Alvarez
Slide 51: Who is Glenview Capital
PAGE 51 Who is Glenview Capital $6B+ New York based Hedge Fund Not an activist fund - HMA is the first time Glenview Capital has proposed fully replacing BOD members Investor in HMA for more than 2 years Own 14.6% of HMA Have $2B in capital invested in the hospital sector Historical track record of
Slide 52: Glenview participants and consent solicitation legend
PAGE 52 GLENVIEW CAPITAL PARTNERS, L.P., GLENVIEW CAPITAL MASTER FUND, LTD., GLENVIEW INSTITUTIONAL PARTNERS, L.P., GLENVIEW OFFSHORE OPPORTUNITY MASTER FUND, LTD., GLENVIEW CAPITAL OPPORTUNITY FUND, L.P., GLENVIEW CAPITAL MANAGEMENT, LLC AND LARRY ROBBINS (COLLECTIVELY, "GLENVIEW") TOGETHER WITH TH
Health Management Associates — Proxy Contest (July 2013) on 6ix